{
    "organizations": [],
    "uuid": "a4915b419b435114041f37a4486efa1974282031",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-inovio-receives-milestone-payment/brief-inovio-receives-milestone-payment-from-medimmune-idUSASB0C02X",
    "ord_in_thread": 0,
    "title": "BRIEF-Inovio Receives Milestone Payment From Medimmune",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Inovio Pharmaceuticals Inc:\n* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:23:00.000+02:00",
    "crawled": "2018-01-09T17:18:43.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "inovio",
        "pharmaceutical",
        "inc",
        "inovio",
        "receives",
        "milestone",
        "payment",
        "medimmune",
        "medi0457",
        "checkpoint",
        "inhibitor",
        "combination",
        "trial",
        "head",
        "neck",
        "squamous",
        "cell",
        "cancer",
        "advance",
        "phase",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}